



- Objective of the Project
- Partners and Procurers
- 3 phases PCP



Need to contact us?

 antisuperbugs.aquas@gencat.cat

 <http://antisuperbugs.eu/>

 +34 935 513 477

@anti_superbugs

ANTI-SUPERBUGS is led by a consortium of healthcare procurers from Spain, Germany, Italy and UK. The PCP aims to get smart ICT solutions developed to detect the presence of resistant microorganisms, give real-time feedback to the user and share the information with the healthcare provider's electronic record systems linking the infection with the place of detection.

Description of the Project

ANTI-SUPERBUGS PCP aims to improve the quality of care processes in hospitals and reduce both the costs and the collateral effects provoked by Multi-Drug Resistant Organisms (MDROs, aka "Superbugs") and other Health Associated Infections, through development and testing of prototypes of devices and ICT services that can: 1) non-invasively test for the presence of MDROs and other pathogens, and 2) provide continuous information and remote alerts to health professionals on contamination by pathogens of high contact surfaces, applicable to existing healthcare environments.

The project, co-funded by EU H2020 Programme, is coordinated by AQuAS that also acts as lead procurer. It currently involves 8 procuring entities (Institut Català d'Oncologia, Universitaetsklinikum Aachen, HELIOS Klinikum Wuppertal, Sheffield Teaching Hospitals NHS Foundation Trust, Provincia Autonoma di Trento, Manchester University Hospitals NHS Foundation Trust, Fundació Mutua de Terrassa and the Turkish Ministry of Health) plus partners with relevant expertise in public procurement (Sara Bedin) and technology (RISE, Acreo).

MDRO infections result in significant morbidity, mortality and increased hospitalization and costs, adversely affecting patient experience. MDROs are invisible to the naked eye and can survive on surfaces for multiple days, being transferred via individuals' contact (patients, staff) or surface contact. It is imperative to provide detection systems that can be easily integrated into healthcare facilities, enabling control of MDROs.

An open PCP will allow R&D service contracts to be awarded to a number of providers, in parallel, in a three-phase approach: 1) Solution design; 2) Prototyping; and 3) Original development and validation & testing. ANTI-SUPERBUGS Prior Information Notice has been published in the Official Journal of the European Union, including information on the Open Market Consultation.



RISE Acreo AB



Sara Bedin